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The fidelity and specificity of information flow within a cell is controlled by scaffolding proteins that assemble and link enzymes into signalling circuits 1, 2 . These circuits can be inhibited by bacterial effector proteins that post-translationally modify individual pathway components [3] [4] [5] [6] . However, there is emerging evidence that pathogens directly organize higher-order signalling networks through enzyme scaffolding 7, 8 , and the identity of the effectors and their mechanisms of action are poorly understood. Here we identify the enterohaemorrhagic Escherichia coli O157:H7 type III effector EspG as a regulator of endomembrane trafficking using a functional screen, and report ADP-ribosylation factor (ARF) GTPases and p21-activated kinases (PAKs) as its relevant host substrates. The 2.5 Å crystal structure of EspG in complex with ARF6 shows how EspG blocks GTPase-activating-protein-assisted GTP hydrolysis, revealing a potent mechanism of GTPase signalling inhibition at organelle membranes. In addition, the 2.8 Å crystal structure of EspG in complex with the autoinhibitory Ia3-helix of PAK2 defines a previously unknown catalytic site in EspG and provides an allosteric mechanism of kinase activation by a bacterial effector. Unexpectedly, ARF and PAKs are organized on adjacent surfaces of EspG, indicating its role as a 'catalytic scaffold' that effectively reprograms cellular events through the functional assembly of GTPase-kinase signalling complex.
To identify new signalling pathways targeted by bacterial pathogens, we used a human growth hormone (hGH) secretion assay 9 to measure the ability of type III and type IV effector proteins to regulate vesicle trafficking through the general secretory pathway (Fig. 1a, b) . Consecutively, each bacterial effector was tagged with enhanced green fluorescent protein (eGFP) and assessed for localization at host organelles (Fig. 1b) . We noted that several type III effectors encoded by the extracellular pathogen enterohaemorrhagic E. coli (EHEC) O157:H7 inhibited host trafficking events, whereas effectors secreted by Salmonella Typhimurium, Legionella pneumophila and Bartonella henslae showed little inhibitory functions, consistent with their intracellular life cycles (Fig. 1b) . In particular, the EHEC type III effector EspG blocked exocytosis of hGH through an unknown molecular mechanism (Fig. 1b) . eGFP-tagged EspG localized to the cis-Golgi apparatus, where it induced severe fragmentation of the organelle (Fig. 1c, d and Supplementary Fig. 1a, b) . The Golgi disruption phenotype was observed when 10 nM recombinant EspG protein was microinjected into cells to mimic the protein concentration delivered by E. coli through the type III secretion apparatus 10 ( Fig. 1d) . In addition, EspG disrupted the recycling endosome compartment in both transfection ( Supplementary Fig. 1c, d ) and microinjection experiments (data not shown). Previous genetic studies have implicated EspG 11, 12 and related Shigella family members 13 in microtubule depolymerization. However, microtubules were intact in EspG microinjected cells (Fig. 1d) , consistent with previous reports showing that these effectors do not disrupt cytoskeletal architectures 14, 15 . Thus, EspG represents a new class of bacterial signalling effector that functionally regulates cargo trafficking from membrane organelles.
We used a yeast two-hybrid screen to identify host enzymes targeted by EspG. The screen resulted in 26 positive interactions with multiple overlapping complementary DNA clones expressing two ARF GTPase family isoforms (ARF1 and ARF6) and three p21-activated kinase family members (PAK1, PAK2 and PAK3) (Fig. 1e, f) . ARF GTPases function within a broad range of organelle systems, where they organize vesicle transport machinery, phospholipids and signalling molecules at membrane microdomains 16, 17 , whereas the PAK family of serine/threonine kinases transduce Cdc42 and Rac1 GTPase signals that establish intracellular polarity 18 . Direct interactions between EspG and the GTPase domain of ARF family members (Fig. 1g ) and the autoinhibitory domain (AID) of PAK kinases (Fig. 1h) were shown by in vitro binding studies using purified recombinant proteins. These findings establish two EspG substrates that are consistent with its regulatory function in host protein trafficking identified here and in bacterial infection studies conducted in vivo 19, 20 . Next we crystallized EspG (residues 42-398) in complex with the GTPase domain of ARF6 (residues 13-175) and solved the structure to a resolution of 2.5 Å (Supplementary Table 1 ). EspG buries 602 Å 2 of ARF6 surface area and the complex interface is mediated by a collaboration of EspG loops (loops connecting b5 and b6, b8 and a6, and b12 and b13) that specifically engage the switch I loop of ARF6 and several residues lining the guanine-nucleotide-binding pocket ( Fig. 2a and Supplementary Fig. 2a, b) . The conformational state and aminoacid sequence of switch I are highly conserved between ARF family members, indicating that the EspG-ARF6 structure illustrates the nature of EspG's interaction with several ARF isoforms ( Supplementary  Fig. 3a, b) . The importance of conserved switch I residues for binding EspG were confirmed by mutational analysis on ARF6 ( Supplementary  Fig. 3c ).
ARF6 is GTP bound in the crystal and adopts an active-state conformation nearly identical to that of ARF6 GTPcS (ref. 21 ; Supplementary Fig. 4a ). Further structural analyses revealed that switch I is inaccessible to EspG when ARF6 adopts the GDP-bound conformation ( Supplementary Fig. 4a ). EspG selectively bound the GTP-loaded forms of ARF1 and ARF6 but did not recognize GDP-ARF complexes (Fig. 2b) . Moreover, EspG interacted with ARF6 GTP in its full-length myristoylated form, which was isolated from membrane fractions ( Supplementary Fig. 4b ). Thus, EspG preferentially targets the active ARF GTP signalling molecule.
COPI coat, vesicle complex adaptors and signalling enzymes primarily associate with switch 2 and the b2/3 interswitch of ARF GTP (refs 22-26; Supplementary Fig. 5a ). Given the frequent occurrence of this binding mode, we were surprised to find that EspG is rotated away from these common binding elements and is positioned directly over the guanine-nucleotide-binding pocket (Fig. 2a, c) . Surprisingly, however, EspG does not function as a guanine nucleotide exchange factor ( Supplementary Fig. 5b , c) or a GTPase-activating protein (GAP) (Fig. 2d , cyan circles). Rather, EspG is appropriately positioned to hinder binding of ARF-GAP and its catalytic access to the c-phosphate of GTP (Fig. 2c) . EspG completely abolished the GAP-stimulated GTPase hydrolysis on lipid-anchored ARF1 (Fig. 2d, diamonds) , in comparison with the fast ARF-GAP reaction (Fig. 2d , blue triangles). The inhibition of GAP by EspG relied on a direct interaction between EspG and ARF because the binding-deficient mutant EspG Glu 392 Arg (characterized in Supplementary Fig. 6 ) had no affect on GAP-stimulated hydrolysis (Fig. 2d, open circles) .
GTP hydrolysis and exchange on ARF is required for proper membrane transport functions, suggesting that EspG inhibits Golgi trafficking by blocking its guanine nucleotide cycle 17, 26 . Several lines of evidence support this idea. First, EspG disrupted the Golgi complex with rapid inhibitory kinetics ( Fig. 2e ) and a phenotype similar to the fungal toxin brefeldin A ( Supplementary Fig. 7a ), a potent ARF1 GTPase inhibitor that also interferes with the guanine nucleotide cycle 27 . Second, microinjection of dominant-negative ARF protein (ARFDN13) caused a significant delay in Golgi disruption induced by EspG (Fig. 2e , open circles). Third, EspG Glu 392 Arg, a mutant that does not interact with host substrates (Supplementary Fig. 6 ), had no affect on Golgi morphology or trafficking function ( Fig. 2e and Supplementary Fig. 7b, c) . Finally, EspG co-localized with the ARF1 effector b-COP (ref. 26 ) on Golgi membranes ( Supplementary Fig. 1b ). These combined structure and cellular studies provide a mechanism for bacterial regulation of membrane trafficking: EspG prevents vesicle transport by directly inhibiting ARF guanine nucleotide turnover on host membranes.
Having established the mechanism of ARF GTPase regulation, we next explored a second possible function of EspG: regulation of PAK family kinases. The EspG-binding site on PAK2 was defined to residues 121-136, a highly conserved sequence that encodes the Ia3-helix within the kinase AID ( Supplementary Fig. 8 ). We crystallized EspG in complex with the PAK2 Ia3-helix fragment and solved the structure to a resolution of 2.8 Å (Supplementary Table 1 ). EspG recognized the initial turn of the Ia3-helix whereas the remainder of the peptide adopted an extended strand conformation that lies orthogonal to the EspG six-stranded b-sheet (Fig. 3a, b) . EspG buries 684 Å 2 of the PAK2 surface area and the binding is primarily supported by a large hydrophobic interface and hydrogen bonding by residues Asn 212 and Asn 323 of EspG (Fig. 3b) . This structural interface was confirmed by a series of in vitro binding studies and kinase assays using PAK2 and EspG mutant proteins ( Supplementary Fig. 9 ).
To determine how EspG may regulate the kinase, we compared the peptide structure from EspG-PAK2 with the structure of Ia3-helix in the autoinhibited PAK1 homodimer 28 ( Fig. 3c) . In autoinhibited PAKs, the Ia3-helix is sandwiched between the kinase domain and the AID, where it has three autoinhibitory functions: (i) it folds onto 
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the EF-and G-helices to block substrate binding; (ii) it positions the 'kinase inhibitory' loop across the enzyme catalytic cleft; and (iii) it stabilizes the AID three-helix bundle maintaining PAK homodimerization (Fig. 3c) . Hence, EspG binding to the Ia3-helix suggested a mechanism for PAK activation. EspG induced a (7.6 6 2.5)-fold (n 5 11) increase in PAK2 activity, a profile that is comparable to PAK stimulation by GTPcS-loaded Cdc42 ((7.8 6 3.4)-fold, n 5 3) (Fig. 3d) . Notably, EHEC type III effectors Map and EspF U showed no PAK stimulatory activity, demonstrating the signalling specificity of EspG (Fig. 3e) .
To gain further insight into the mechanism of kinase activation, we first examined the details of the EspG-PAK2 interface. EspG residue Asn 212 probably initiates the kinase reaction because this residue engages the surface-accessible residues Asp 131 and Ser 132 in the autoinhibited PAK homodimer (Fig. 3b and Supplementary Fig. 10 ). On initial recognition, EspG displaces the Ia3-helix by reorganizing its secondary structure and by displacing side chains that normally contact the autoinhibitory interface between the kinase domain and the AID (Fig. 3c) . These data suggest a novel allosteric mechanism for PAK activation. To further confirm that PAK is stimulated by local perturbations in the environment surrounding Ia3, we mutated the hydrophobic PAK2 residues Val 123 and Phe 129 that stabilize the AID and the kinase domain, respectively. Both Val 123 Asp and Phe 129 Asp resulted in a constitutively active kinase with more than 60-fold enhancement of substrate phosphorylation (Fig. 3f) . We note that the mechanism of EspG binding to PAK is structurally distinct from that of Cdc42 binding 28 , indicating that the catalytic machinery of EspG is a unique bacterial invention.
The two EspG structures reported here are nearly identical, with a root mean squared deviation of 0.612 Å over 349 Ca atoms. As shown in Fig. 4a, ARF6 and PAK2 occupy distinct, non-overlapping binding sites on adjacent surfaces of EspG. Consistent with this view, EspG nucleates a trimeric complex between the kinase and GTPase in solution ( Supplementary Fig. 11 ). This complex could also be reconstituted on Golgi mimetic liposomes (Fig. 4b) . ARF1 GTP recruited EspG to the artificial membrane surface (Fig. 4b, lane 4) , which in turn localized PAK2 to these sites (Fig. 4b, lane 6) . Notably, PAK2 localization was strictly dependent on formation of the EspG-ARF1 GTP complex (Fig. 4b, lanes 6-8) and ARF1 tethering to the membrane (Fig. 4b,  lanes 9 and 10) . As predicted by these findings, EspG co-localized with ARF1 at the Golgi (Fig. 4c) . We further speculated that PAK would also be recruited to these sites. To test this hypothesis, an in vivo 'activity' probe was engineered by fusing the PAK2 Ia3-helix sequence (residues 121-136) to the carboxy terminus of the mCherry fluorophore. The PAK2 probe recognized cellular EspG and was targeted to the Golgi complex in 78 6 5% of EspG-transfected cells (Fig. 4c) . By comparison, mutant EspG Asn 212 Ala that lacked all kinase stimulatory activity ( Supplementary Fig. 9 ) localized to the Golgi complex but did not recruit PAK2 to these sites (Fig. 4c) . Together, our studies support the function of EspG as a catalytic scaffold that links GTPase inhibition with kinase signal transduction pathways at membrane organelles (Fig. 4d) .
EspG belongs to large family of type III effectors secreted by diverse bacterial pathogens. Our studies show that EspG has structural homology with VirA (refs 14, 15) from Shigella flexneri, suggesting that it too may function as an enzyme scaffold (root mean squared deviation, 3.1 Å ; Z-score, 5.9) (Supplementary Fig. 12 ). However, a detailed structural comparison indicates that VirA is unlikely to target the same signalling pathways as EspG during Shigella pathogenesis ( Supplementary Fig. 12 ). We provide mechanistic insights and structural evidence that EspG harbours two unique pathogenic activities, ARF GTPase inhibition and PAK stimulation. Moreover, EspG targets PAK to specific membrane surfaces through its association with ARFs. From a strategic point of view, the assembly of an artificial enzyme complex enables bacteria to precisely control signalling events with little competition between endogenous regulatory systems. Thus, it is intriguing to speculate that EspG organizes a higherorder signalling network to effectively subvert key cellular processes including cell polarity, adhesion, receptor trafficking and protein secretion. 
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Recombinant protein preparation and cloning were done using standard methods. In immunofluorescence experiments, we transfected cells with Fugene 200 or microinjected them with 10 nM protein, where indicated. We performed kinase assays with rabbit pEGFP-PAK2, which was immunoprecipitated from 293T cell lysates and incubated with the protein of interest in the presence of MBP, 10 mM ATP and 5 mCi c 32 P[ATP]. Reactions were stopped by the addition of SDS buffer, separated by SDS-polyacrylamide gel electrophoresis and kinase activity was measured as 32 P counts per minute. EspG-ARF6 and EspG-PAK2-Ia3 were purified by ion exchange and gel filtration chromatography and crystallized by the hanging-drop vapour diffusion method. We collected X-ray diffraction data at the Structural Biology Center, Advanced Photon Source, Argonne National Laboratory (USA). The structure of EspG-ARF6 was phased to a resolution of 2.5 Å by the multiwavelength anomalous dispersion method using selenomethionine-labelled EspG and ARF6 proteins. The EspG-PAK2 structure was solved to a resolution of 2.8 Å by the molecular replacement method using the EspG monomer of the EspG-ARF6 structure as the initial search model. Further details can be found in Supplementary Information.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
METHODS
Plasmids. The espG gene from EHEC O157:H7 was PCR cloned in-frame into pEGFP-C2 (Clontech) and pcDNA3.1-mCherry. For bacterial expression, 38 and 41 amino-acid N-terminal deletions (39-398 and 42-398) of EspG were PCR subcloned into pGEX-4T1 (GST-tag) (Amersham), pProEX-HTb (6xHis tag) (Novagen) and pET28b-MalE (6xHis tag, MalE-tag) vectors. EspG mutants were generated with QuickChange site-directed mutagenesis (Stratagene) following manufacturer's instructions. N-terminal deletions of ARF GTPases (ARF1D17, ARF5D17 and ARF6D13) and ARL proteins (ARL1D17 and ARL2D16) were PCR subcloned into pGEX-4T1 and pProEX-HTb vectors. Human PAK1 construct was obtained from Dr Gary Bockoch (TSRI, La Jolla, California), and rabbit PAK2 and PAK3 were obtained from Dr Melanie Cobb (UTSW). PCR cloning was used to generate variable-length constructs of PAK isoforms in pGEX-4T1 vector. All constructs were verified by DNA sequencing. Yeast two-hybrid system. The yeast expression vector pLexA encoded a gene with an NH2-terminal LexA-binding domain and residues 1-398 of EHEC EspG. Day 9.5 and 10.5 mouse embryo cDNA library (250 mg) in VP16 were screened using the yeast two-hybrid system. Protein purification for in vitro assays. Recombinant proteins were produced in BL21-DE3 E. coli strains. Protein expression was induced with 0.4 mM IPTG for 16 h at 18 uC. Bacterial pellets were lysed in either His buffer (100 mM HEPES, pH 7.5, 300 mM NaCl) or GST buffer (TBS; 50 mM Tris pH 7.5, 150 mM NaCl, 2 mM DTT) supplemented with protease cocktail (Roche). Proteins were purified with nickel agarose (Qiagen) or glutathione Sepharose (Amersham Biosciences) following manufacturer's instructions. Eluted proteins were buffer exchanged into TBS using concentration centrifugal columns (Millipore), glycerol was added to 15% and the proteins were then stored at 280 uC. In vitro GST pull-downs. Protein interactions were examined through GST pulldown assays. Unless otherwise stated, 15 mg of recombinant GST proteins immobilized to glutathione Sepharose were incubated with 20 mg of 6xHis-and/or MalE-tagged proteins for 1 h at 4 uC. Samples were washed three times in TBS supplemented with 0.5% Triton X-100. Proteins were eluted from beads with Laemelli sample buffer and were separated by SDS-polyacrylamide gel electrophoresis and stained with Coomassie blue. For nucleotide loading, ARF1D17 and ARF6D13 were incubated in nucleotide loading buffer (40 mM HEPES, 150 mM NaCl, 2 mM EDTA, 10% glycerol) with 10 mM of either GDP or GTP for 30 min at 37 uC, and then MgCl 2 was added to 10 mM and the reaction was transferred to ice after 15 min at room temperature (25 uC). Kinase assays. To obtain full-length PAK2 kinase, 10-cm dishes with 293A cells were transfected with 5 mg rabbit PAK2 cDNA in pEGFP-C2 vector and expressed for 48 h post-transfection. Cells were broken in lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.5% Triton X-100). PAK2 kinase was purified by immunoprecipitation with 1:1,000 polyclonal anti-GFP antibody (Clontech) and 25 ml protein A/G slurry for 1 h at 4 uC. Beads were washed twice with lysis buffer and twice with kinase buffer (40 mM HEPES, pH 7.5, 10 mM MgCl 2 ). MBP (5 mg) and 2 mM activating proteins (that is, EspG or Cdc42) were added to the beads for a total volume of 30 ml. The reaction was equilibrated on ice for 30 min. The kinase activity was initiated by an addition of 10 mM ATP and 5 uCi ATPcP 32 . After 5 min at room temperature, the reaction was stopped with 30 ml 32 Laemelli sample buffer. Contents were separated by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose membrane and either analysed by western blot (1:5,000 monoclonal anti-GFP) or exposed by autoradiography. Bands were cut out and the radioactivity signal measured on a scintillation counter. Cell microinjection, transfections and immunofluorescence microscopy. Normal rat kidney cells were microinjected with EspG proteins using a semiautomatic InjectMan NI2 micromanipulator (Eppendorf). A needle concentration of 10 nM was calculated to inject between 5,000 and 20,000 copies because we microinjected ,5% cell volume, giving a final estimated cellular concentration of 50 pM in a cell volume of 5,000 mm 3 . HeLa and HEK293A cells were transfected using calcium phosphate. At 16-18 h post-transfection, cells were fixed with 3.7% formaldehyde and stained with antibodies for immunofluorescence. In co-transfection experiments, equal amounts of DNA were used for each sample. Brefeldin A treatment was performed by adding 5 mg ml 21 of brefeldin A to the medium before fixation with formaldehyde. As a negative control, ethanol was added to the medium. All immunofluorescence images were acquired with a Zeiss LSM 5 Pascal confocal microscope. Golgi, endosomes and microtubules were detected using anti-GM130 (transduction labs), anti-EEA1 (transduction labs) and anti-a-tubulin (Sigma) antibodies, respectively. hGH trafficking assay. hGH trafficking assays were performed as described previously 9 . Briefly, HeLa cells (50% confluence) were transfected with 1 mg of 4xFKBP-hGH (Ariad Pharmaceutical, Inc.; http://www.ariad.com/regulationkits; source of material, David Bernstein) and either 0.5 mg eGFP-EspG or pEGFP control plasmid with Fugene6 (Roche). Sixteen hours later, the medium was replaced with medium containing AP21998 (final concentration, 2 mM) or vehicle control. AP21998 was incubated with the cells for 2 h before the supernatant was collected. The supernatant was then diluted 100-fold and compared against a hGH standard curve (12.5-400 pg ml 21 ) for the quantification of hGH released using an hGH enzyme-linked immunosorbent assay (Roche). For no drug controls, 100% ethanol (2 ml) was incubated with the cells for 2 h. Liposome pull-downs and GAP assays. Liposome preparation: Lipids were purchased in powder form from Avanti Polar Lipids. Golgi mimetic liposomes were created by combining 20 mol% DOGS-NTA with DOPC, DOPE, DOPA, DOPS, PI, PI 4 P and PI 4,5 P 2 in the molar ratios reported previously 29 . Total lipid (5 mM) was solubilized in chloroform, dried under an anhydrous nitrogen stream and further dried in a vacuum desiccator for approximately 5 h. Dried lipids were hydrated with liposome-binding buffer (20 mM Tris-HCl, pH 7.6, 50 mM NaCl, 10 mM MgCl 2 ) and vigorously vortexed between five freeze-thaw cycles (liquid nitrogen and 80 uC to ensure appropriate phase transition and dispersion of the various lipids), after which liposomes were generated by means of ultrasonication in a bath sonicator (Laboratory Supplies Company). Liposomes were collected from the supernatant after centrifugation (2,500g for 5 min) and used in subsequent assays.
Liposome pull-down assays: Liposomes were prepared as described above. ARF1 GTP loading was carried out by incubating purified 6xHis-tagged ARF1DN17 in nucleotide exchange buffer (20 mM Tris-HCl, pH 7.6, 50 mM NaCl, 5 mM EDTA, 10% glycerol, 1 mM DTT) with 100 mM GTP. After incubation at 37 uC for 30 min, 10 mM MgCl 2 was added to stabilize ARF1(GTP). The requisite volume of ARF1(GTP), GST PAK (residues 121-136) or EspG was added to bring the protein concentration to 3 mM in a 100-ml volume. Liposomes were added for a final lipid concentration of 10 mM and reactions proceeded at room temperature for 30 min. Samples were subjected to centrifugation at 100,000g in a Beckman TLA100.3 rotor and a Beckman TL100 ultracentrifuge at 4 uC for 1 h. Supernatant and pellet were separated and analysed on a 12.5% polyacrylamide gel and visualized with Coomassie blue.
GTP hydrolysis assays: ARF1 was incubated in nucleotide exchange buffer with 250 nM c In the case of hydrolytic protection assays, EspG or EspG(E392R) was added 5 min before the addition of rat ARFGAP1. Aliquots (5 ml) of the 50-ml reaction were removed at times indicated, added to 5 ml ice-cold binding buffer (TBS 1 10 mM MgCl 2 ) and vacuumfiltered through nitrocellulose membranes. Membranes were washed three times with ice-cold binding buffer and subjected to scintillation counting. Data analysis was carried out in GRAPHPAD PRISM 5.0b. Crystallization and structure determination. Protein expression and purification: A stable protein fragment of EspG residues 42-398 was identified by limited proteolysis and mass spectrometry. cDNA-encoding EHEC O157:H7 EspG residues 42-398 and human ARF6 residues 14-175 were synthesized by PCR and ligated into the pPRO-EX-HTb expression vector. The resulting plasmids were then transformed into the E. coli strain BL21-DE3. Protein expression was induced by 1 mM IPTG overnight at 16 uC and proteins were purified on Ni-NTA agarose, concentrated to 10 mg ml 21 in TBS buffer with 5% glycerol, snap-frozen in liquid nitrogen and stored at 280 uC. The Se-Met variant of EspG and ARF6 was expressed in methionine auxotrophic E. coli strain B834-DE3 and grown in minimal medium supplemented with natural amino acids and Se-Met. Expression and purification were unchanged. EspG-ARF6 complex was formed overnight at room temperature in the presence of 1:100 TEV protease to cleave the 6xHis tag. The complex was purified by successive anion exchange (Q-HP) and gel filtration (Superdex 200 GL) chromatography and concentrated to 7 mg ml 21 in 25 mM Tris, pH 7.5, and 50 mM NaCl. For the PAK2 crystal trials, EspG protein was expressed and purified identically to that described. However, after the anion exchange, EspG was incubated with a fivefold molar excess of PAK2 peptide (residues 121-136). The complex was purified by gel filtration as described.
Crystallization and X-ray diffraction data collection: Crystals of EspG-ARF6 were grown using the hanging-drop vapour diffusion method from drops containing 2 ml protein (7 mg ml 21 ) and 1 ml of reservoir solution (0.1 M sodium acetate, pH 5.0, 2% PEG4000, 5% 2,3-methylpentanediol (MPD)), and equilibrated over 500 ml of reservoir solution. Bipyramid-like crystals appeared after 1 d at 20 uC and grew to their maximal extent in 2-3 d. Crystals were relatively large in all three dimensions (0.3 3 0.6 3 0.3 mm 3 ). Cryo-protection was performed by transferring the crystals to a final solution of 37% MPD, 0.1 M sodium acetate, pH 5.0, and 2% PEG4000, increasing in 5% steps of MPD over the course of 10 min at 20 uC. Crystals were flash-frozen using liquid nitrogen. EspG-ARF6 crystals had the symmetry of space group P4 3 2 1 2 with unit-cell parameters of a 5 b 5 104.6 Å and c 5 98.3 Å , and contained one molecule each of EspG and RESEARCH LETTER ARF6 per asymmetric unit. EspG-ARF6 crystals diffracted isotropically to a d min of 2.50 Å when exposed to synchrotron radiation.
Crystals of EspG-PAK2 were grown using the hanging-drop vapour diffusion method from drops containing 1 ml protein (12 mg ml 21 ) and 1 ml of reservoir solution (0.1 M Tris, pH 8.0, 0.25 M sodium chloride and 20% PEG4000) and equilibrated over 500 ml of reservoir solution. Plate-like crystals appeared after 2 d at 20 uC and grew to their maximal extent by 4-5 d. Crystals were large in two dimensions (0.2 3 0.5 mm 2 ) and relatively thin (0.1 mm). Cryo-protection was performed by transferring the crystals to a final solution of 15% ethylene glycol, 22% PEG4000, 0.1 M Tris, pH 8.0, and 0.25 M sodium chloride, increasing in 5% steps of ethylene glycol over the course of 10 min at 20 uC. Crystals were flash-frozen using liquid nitrogen. EspG-PAK crystals had the symmetry of space group P2 1 2 1 2 1 with unit-cell parameters of a 5 86.7 Å , b 5 104.6 Å and c 5 192.0 Å , and contained four molecules of EspG-PAK per asymmetric unit. EspG-PAK crystals diffracted to a d min of 2.85 Å when exposed to synchrotron radiation. Data were indexed, integrated and scaled using the HKL-3000 program package 31 . Data collection statistics are provided in Supplementary Table 1 . Phase determination and structure refinement: Phases for the EspG-ARF6 complex were obtained from a three-wavelength anomalous dispersion experiment using selenomethionyl-substituted protein with data to a d min of 2.50 Å . Fifteen selenium sites were located using the program SHELXD 32 ; this represented nine single-occupancy selenium sites and six half-occupancy selenium sites per EspG-ARF6 heterodimer. Phases were refined with the program MLPHARE, resulting in an overall figure of merit of 0.41 for data between 32.9 and 2.50 Å . Phases were further improved by density modification with the program DM 33 , resulting in a figure of merit of 0.70. An initial model containing 97% of all EspG residues was automatically generated by alternating cycles of the programs RESOLVE 34 and BUCCANEER 35 . Inspection of the electron density map revealed density for the ARF6 molecule, but the automatic model-building programs were unable to build a complete model for this protein. Placement of a model for ARF6 in the cell was performed by means of molecular replacement in the program PHASER 36 using the GTPcS-bound ARF6 (Protein Data Bank ID, 2J5X) as a search model.
Additional residues for EspG were manually modelled in the program O
37
. Refinement was performed with the data collected at the selenium peak wavelength to a resolution of 2.50 Å using the program PHENIX 38 with a random 5% of all data set aside for an R free calculation. The current model contains one EspG and one ARF6 monomer; included are residues 47-395 of EspG, residues 14-174 of ARF6, one Mg 21 -GTP and 138 water molecules. The R work value is 22.5% and the R free value is 32.4%. The higher-than-average R free value is probably due to the relative dearth of lattice contacts for the ARF6 molecule, as evidenced by weak electron density for the portions of ARF6 that are distal to the EspG-binding site.
The density for the portions of ARF6 (residues 20-63 and 152-170) that are proximal to EspG and to the Mg 21 -GTP is strong and well connected. A Ramachandran plot generated with MOLPROBITY 39 indicated that 99.0% of all protein residues are in allowed regions.
Phases for EspG-PAK were obtained by means of molecular replacement in the program PHASER using the coordinates of EspG from the EspG-ARF6 structure as a search model. Model building and refinement was performed as described above, with the following modification: owing to the lower resolution of the data, restrained non-crystallographic symmetry was implemented during refinement. The current model contains four EspG monomers and four PAK peptides. Included are EspG residues 42-158, 163-318 and 321-397 and PAK residues 122-135, in complex A; EspG residues 43-397 and PAK residues 122-133, in complex B; EspG residues 42-158, 163-316 and 322-395 and PAK residues 123-132, in complex C; and EspG residues 42-158, 163-317 and 320-395 and PAK residues 122-134, in complex D. The R work value is 20.3% and the R free value is 28.6%. A Ramachandran plot generated with MOLPROBITY indicated that 99.4% of all protein residues are in allowed regions. Phasing and model refinement statistics are provided in Supplementary Table 1 .
Combination models were generated by structural alignment of homologous or identical proteins from separate independent structures where applicable, using PYMOL.
